Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

BiDil's impact

Nature Biotechnology volume 23, page 1343 (2005)Cite this article

A Correspondence to this article was published on 01 November 2005

Access through your institution
Buy or subscribe

To the editor:

We were greatly disturbed to read your editorial in the August issue (Nat. Biotechnol. 23, 903, 2005) which made disparaging comments about BiDil, a new heart failure medication for blacks that has been shown clearly to be safe and effective. Despite misleading claims in your editorial, research shows African Americans do bear a disproportionate burden of heart failure. Therefore, it is important to remember three crucial facts.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hunt, S.A. et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. 5.2 Ethnic Considerations (American College of Cardiology, Bethesda, MD, 2005). http://www.acc.org/clinical/guidelines/failure//index.pdf

    Google Scholar 

  2. US Department of Health and Human Services; US Centers for Disease Control and Prevention; US National Center for Health Statistics; Office of Analysis, Epidemiology, and Health Promotion; Compressed Mortality File compiled from CMF 1999–2001, series 20, No. 2G 2004 on CDC WONDER online database. http://wonder.cdc.gov/mortICD10J.html

Download references

Author information

Authors and Affiliations

  1. National Minority Health Month Foundation, 1200 New Hampshire Avenue, NW Suite 575, Washington, 20036, DC, USA

    Gary Puckrein

  2. A-HeFT investigator, the University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, 75390, TX, USA

    Clyde W. Yancy

Authors
  1. Gary Puckrein
    View author publications

    Search author on:PubMed Google Scholar

  2. Clyde W. Yancy
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Puckrein, G., Yancy, C. BiDil's impact. Nat Biotechnol 23, 1343 (2005). https://doi.org/10.1038/nbt1105-1343a

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt1105-1343a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing